drugset / Trial / NCT00038909
Study Evaluating ReFacto in Hemophilia A
Treatment
Summary
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).
Timeline
- Start
- 1994-09
- Primary completion
- 2001-05
- Completion
- 2001-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BDDrFVII | Unknown | — | — |